EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database

Aliza B Ben-Zacharia iD, Jenny J Feng iD, Brandon P Moss iD, Nicholas Belviso, Yu Zhang, Filipe Branco, Jason P Mendoza iD, James B Lewin iD, Sarah M England iD

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2024-0071 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Aliza B Ben-Zacharia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hunter College, Bellevue School of Nursing, NY 10010, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Fumarates, Drug Substitution, Rituximab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Anti-CD20 monoclonal antibodies and fumarates are common multiple sclerosis (MS) disease-modifying therapies (DMTs). Data on switching from anti-CD20s to other DMTs are limited. This retrospective, observational study of the US Komodo Health Sentinel claims database aimed to evaluate a de-escalation strategy in a real-world cohort, comparing clinical characteristics, relapses, healthcare encounters (HCEs) and healthcare costs (HCCs) between patients aged ≥18 years with stable MS who switched from anti-CD20s to fumarates (‘Switchers’) versus patients who stayed on anti-CD20s (‘Stayers’). Materials & methods: Patients with MS (diagnosed 1 January 2015–31 August 2022) were propensity score matched 5:1 (Stayers:Switchers) and followed from index to end of study; end of insurance eligibility; >45-day gap in index DMT; or DMT switch. Primary outcomes were clinical characteristics and claims-based annualized relapse rate (ARR). Rates of HCEs and HCCs were estimated.

Results

Baseline characteristics were well balanced between cohorts (Stayers, n = 540; Switchers, n = 108). Mean (SD) duration of post-index follow-up was 341.4 (250.0) days for both cohorts. Mean (SD) ARR was 0.08 (0.41; Stayers) versus 0.14 (0.5; Switchers; p = 0.3). Twenty-one Stayers (3.9%) and 1 Switcher (0.9%) were hospitalized for infections, with mean stays of 9.9 and 1 day, respectively. Mean annualized all-cause HCEs were similar between cohorts; annualized inpatient infection-related HCEs were higher for Stayers versus Switchers (mean difference: -0.05; p = 0.005). Annualized all-cause HCCs were similar between cohorts; Switchers had lower annualized infection-related HCCs overall (mean difference: -$2412; p = 0.002) and in the inpatient setting (mean difference: -$2325; p = 0.002).

Conclusion

After 1 year, no significant differences in ARR emerged between cohorts. Switchers experienced lower inpatient infection-related HCEs, shorter inpatient infection-related hospital stays and lower overall infection-related HCCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisFumaratesDrug SubstitutionRituximabHumansRetrospective StudiesFemaleMaleAdultUnited StatesMiddle AgedTreatment OutcomeRecurrenceHealth Care CostsDatabases, FactualInsurance Claim ReviewPropensity Score

Stichwörter der Autor:innen

anti-CD20 monoclonal antibodiesde-escalationfumarateshealthcare costshealthcare encountersmultiple sclerosisswitching

Substanzen

FumaratesRituximab

Autor:innen und Institutionen

  • Hunter College, Bellevue School of Nursing, NY 10010, USA.
  • Phillips School of Nursing at Mount Sinai, NY 10035, USA.
  • Ochsner Medical Center, New Orleans, LA 70121, USA.
  • Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Biogen, Cambridge, MA 02142, USA.
  • Formerly: Biogen, Cambridge, MA 02142, USA.

ORCID-Profile: Aliza B Ben-Zacharia, Jenny J Feng, Brandon P Moss, Jason P Mendoza, James B Lewin, Sarah M England

Zitieren

APA

Ben-Zacharia, A. B., Feng, J. J., Moss, B. P., Belviso, N., Yu Zhang, Branco, F., Mendoza, J. P., Lewin, J. B., & Sarah M England (2025). Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0071

Vancouver

Ben-Zacharia AB, Feng JJ, Moss BP, Belviso N, Yu Zhang, Branco F, et al. Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0071

BibTeX
@article{BenZacharia2025,
  author = {Ben-Zacharia, Aliza B and Feng, Jenny J and Moss, Brandon P and Belviso, Nicholas and Yu Zhang and Branco, Filipe and Mendoza, Jason P and Lewin, James B and Sarah M England},
  title = {Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2024-0071}
}
Kostenlos starten →